SynAct Pharma (OM:SYNACT) - 주가, 뉴스 및 분석

SYNACT 주식 개요

임상 단계의 생명공학 회사인 SynAct Pharma AB는 스웨덴에서 염증성 질환 치료를 위한 의약품을 연구 및 개발하는 회사입니다. 자세한 내용

SYNACT 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

위험 분석

수익이 1백만 달러 미만인 경우 ( SEK0 )

지난 5년간 매년 수익이 42.9% 씩 감소했습니다.

지난 1년 동안 주주가 희석되었습니다.

의미 있는 시가총액이 없습니다. ( SEK385M )

+ 1 더 많은 위험

SynAct Pharma AB 경쟁사

Initiator Pharma

OM:INIT

SEK 362.8m

Mendus

OM:IMMU

SEK 418.9m

Lipum

OM:LIPUM

SEK 354.2m

Curasight

NGM:CURAS

DKK 225.4m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 SynAct Pharma
과거 주가
현재 주가	SEK 9.33
52주 최고치	SEK 13.80
52주 최저치	SEK 4.98
베타	0.65
11개월 변경	4.13%
3개월 변경 사항	12.82%
1년 변경 사항	41.15%
33년 변화	-92.92%
5년 변화	-5.76%
IPO 이후 변화	79.42%

최근 뉴스 및 업데이트

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

Sep 18

Recent updates

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

Sep 03

SynAct Pharma (NGM:SYNACT) Is In A Good Position To Deliver On Growth Plans

Apr 07

Companies Like SynAct Pharma (NGM:SYNACT) Are In A Position To Invest In Growth

Dec 23

주주 수익률

	SYNACT	SE Biotechs	SE 마켓
7D	8.5%	-0.4%	0.1%
1Y	41.1%	15.1%	11.8%

수익률 대 산업: SYNACT 지난 1년 동안 15.1 %를 반환한 Swedish Biotechs 산업을 초과했습니다.

수익률 대 시장: SYNACT 지난 1년 동안 11.8 %를 반환한 Swedish 시장을 초과했습니다.

가격 변동성

Is SYNACT's price volatile compared to industry and market?
SYNACT volatility
SYNACT Average Weekly Movement	9.5%
Biotechs Industry Average Movement	9.3%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

안정적인 주가: SYNACT 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: SYNACT 의 주간 변동성( 9% )은 지난 1년 동안 안정적이었지만 여전히 Swedish 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2012	5	Jeppe Ovlesen	synactpharma.com

임상 단계의 생명공학 회사인 SynAct Pharma AB는 스웨덴에서 염증성 질환 치료를 위한 의약품을 연구 및 개발하는 회사입니다. 이 회사는 류마티스 관절염, 특발성 막성 신증, 바이러스 유발 호흡 부전 치료를 위한 임상 2상 약물 후보물질인 AP1189를 개발하고 있습니다. 수술 시 장기 부전 예방을 위한 전임상 시험 중인 첨단 펩타이드 작용제인 TXP-11과 자가 면역 및 염증성 질환 치료를 위한 다양한 약물 프로그램을 개발하고 있습니다.

SynAct Pharma AB 기본 사항 요약

SynAct Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SYNACT 기본 통계
시가총액	SEK 385.30m
수익(TTM)	-SEK 154.57m
수익(TTM)	n/a

0.0x

P/S 비율

-2.5x

P/E 비율

SYNACT 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SYNACT 손익 계산서(TTM)
수익	SEK 0
수익 비용	SEK 0
총 이익	SEK 0
기타 비용	SEK 154.57m
수익	-SEK 154.57m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

Feb 18, 2025

주당 순이익(EPS)	-3.74
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

SYNACT 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

SYNACT 주식 개요

위험 분석

SynAct Pharma AB 경쟁사

OM:INIT

SEK 362.8m

OM:IMMU

SEK 418.9m

OM:LIPUM

SEK 354.2m

NGM:CURAS

DKK 225.4m

가격 내역 및 성능

최근 뉴스 및 업데이트

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 44.902176 million.

SynAct Pharma AB to Report Fiscal Year 2024 Results on Feb 18, 2025

SynAct Pharma AB Initiates the Phase 2b Advance Study with Resomelagon (AP1189) in the US

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon

Recent updates

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 44.902176 million.

SynAct Pharma AB to Report Fiscal Year 2024 Results on Feb 18, 2025

SynAct Pharma AB Initiates the Phase 2b Advance Study with Resomelagon (AP1189) in the US

We Think SynAct Pharma (STO:SYNACT) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon

Chief Operating Officer recently bought kr1.9m worth of stock

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 49.239162 million.

New major risk - Revenue and earnings growth

Chief Operating Officer recently sold kr145k worth of stock

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 45 million.

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

New major risk - Financial position

SynAct Pharma AB to Report Q3, 2024 Results on Oct 30, 2024

SynAct Pharma Announces Additional Data from the Expand P2b Clinical Trial Supporting Continued Development of the Compound in Rheumatoid Arthritis

SynAct Pharma AB to Report Q4, 2023 Results on Feb 23, 2024

High number of new and inexperienced directors

Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024

Synact Pharma Expands Its Rheumatology Clinical Advisory Board with Three New Highly Experienced Advisors

SynAct Pharma AB, Annual General Meeting, May 23, 2024

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 60.525 million.

SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate

SynAct Pharma AB Announces Additional Data from the Expands P2b Clinical Trial Further Supporting Efficacy and Activity seen in Patients with Elevated CRP

SynAct Pharma AB Announces Additional Data from the EXPAND P2b Clinical Trial and Identifies Population with Responsiveness to Resomelagon

Synact Pharma Announces Top Line Data from the 12-Week Expand P2b Clinical Trial in Severe Active Newly Diagnosed Rheumatoid Arthritis Patients

SynAct Pharma AB (Publ) Completes Dosing in Part A of Combined Phase 2A/B Resomelagon (AP1189) in Rheumatoid Arthritis (RA)

SynAct Pharma AB (publ) Completes Patient Recruitment for Part A of Combined Phase 2a/b RESOLVE Study of Resomelagon (AP1189) in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces the Completion of Dosing in the Phase 2b Expand Study of Resomelagon (AP1189) in Early Severe Rheumatoid Arthritis Patients

Chief Operating Officer recently bought kr78k worth of stock

SynAct Pharma AB Announces Appointment of Thomas Von Koch as Board Member

SynAct Pharma AB Appoints Björn Westberg as Chief Financial Officer

SynAct Pharma AB to Report Q1, 2023 Results on May 05, 2023

SynAct Pharma AB (OM:SYNACT) completed the acquisition of TXP Pharma AG from Boesen Biotech ApS, GL Capital AB, TJ Biotech Holding ApS, Quantass ApS, and James Knight.

SynAct Pharma AB Announces Change in Nomination Committee Prior to Agm 2023

Chief Operating Officer recently sold kr3.4m worth of stock

SynAct Pharma AB (OM:SYNACT) entered into a conditional agreement to acquire TXP Pharma AG from Boesen Biotech Aps, Glcapital Ab, TJ Biotech Holding ApS, Quantass ApS, and James Knight for approximately SEK 190 million.

No independent directors

SynAct Pharma AB Receives IND Clearance from the FDA for Phase 2A/B Trial of Ap1189 in Ra

SynAct Pharma AB, Annual General Meeting, May 25, 2023

Synact Submits Ind and Recruits First Patient

Synact Pharma Submits IND for US Phase 2A/B Clinical Trial

SynAct Pharma AB (Publ) Enrolls First Patient in Phase 2b Trial of Ap1189 in RA

SynAct Pharma AB Announces Approval of Amended Study Protocol for the Phase 2A Study in iMN

Here's Why We're Watching SynAct Pharma's (STO:SYNACT) Cash Burn Situation

SynAct Pharma AB (publ) Announces That the Clinical Trial Application to Initiate the Clinical Phase 2B Study, Expand

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

Synact Pharma Receives pre-IND Response from the U.S. Food and Drug Administration

SynAct Pharma Submits CTA for Clinical Phase 2b Study in RA

John Haurum Declines Re-Election as Board Member of SynAct Pharma AB

SynAct Pharma AB Completes Clinical Pharmacokinetic Test of Ap1189 Tablet

No independent directors

Is SynAct Pharma (NGM:SYNACT) In A Good Position To Deliver On Growth Plans?

SynAct Pharma AB Announces Additional Data from the BEGIN Study

SynAct Pharma AB Reports Positive PK Data on AP1189 Tablets

SynAct Pharma AB Completes Patient Recruitment to the Phase 2A Begin Study of Ap1189 in Early Severe Rheumatoid Arthritis

Here's Why We're Not Too Worried About SynAct Pharma's (NGM:SYNACT) Cash Burn Situation

SynAct Pharma AB Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis